ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions
View by Date

Friday, November 6, 2020

9:00AM-11:00AM
Abstract Number: 0366
Symptoms of Peripheral Arthritis Are Significantly Improved in Patients with Ankylosing Spondylitis Treated with Secukinumab
Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster I
9:00AM-11:00AM
Abstract Number: 0095
Systematic Evaluation of Nine Monogenic Autoinflammatory Diseases Reveals Common and Disease-Specific Correlations with Allergy-Associated Features
Miscellaneous Rheumatic & Inflammatory Diseases Poster I: Diagnosis and Testing
9:00AM-11:00AM
Abstract Number: 0245
Systemic Lupus Erythematosus Phenotype Risk Score Identifies Undiagnosed Cases in a Large Electronic Health Record
SLE – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Manifestations
9:00AM-11:00AM
Abstract Number: 0269
Systemic Lupus Erythematosus with Libman-Sacks Endocarditis Increases Inpatient Mortality
SLE – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Manifestations
9:00AM-11:00AM
Abstract Number: 0426
T-Cell Receptor (TCR) Sequencing Reveals Decreased Diversity and Clonotypic Expansion of T-cells in Relapsing Polychondritis (RP)
Vasculitis – Non-ANCA-Associated & Related Disorders Poster I
9:00AM-11:00AM
Abstract Number: 0319
Target Outcomes in Psoriatic Arthritis: Simultaneous Achievement of ACR50-Psoriasis Area and Severity Index 100 and Beyond: Insights from Open-Label, Assessor-Blinded Study at Week 24
Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster I: Psoriatic Arthritis
9:00AM-11:00AM
Abstract Number: 0288
Targeted Sequencing Revealed Novel Candidate Genetic Contributions to Lupus Nephritis in a Cohort of Swedish Patients with Systemic Lupus Erythematosus
SLE – Etiology & Pathogenesis Poster
9:00AM-11:00AM
Abstract Number: 0103
The Association of Methotrexate, Sulfasalazine and Hydroxychloroquine Use with Incident Fractures in Postmenopausal Women with Rheumatoid Arthritis: Findings from the Women’s Health Initiative
Osteoporosis & Metabolic Bone Disease Poster
9:00AM-11:00AM
Abstract Number: 0096
The Bicipital Stress Test: A Maneuver to More Accurately Diagnose Bicipital Tendinitis and Its Referred Pain Patterns
Miscellaneous Rheumatic & Inflammatory Diseases Poster I: Diagnosis and Testing
9:00AM-11:00AM
Abstract Number: 0197
The Clinical and Laboratory Features of Seronegative Rheumatoid Arthritis with and Without Malignancy
RA – Diagnosis, Manifestations, & Outcomes Poster I: Multimorbidity
9:00AM-11:00AM
Abstract Number: 0266
The Correlation Between Pregnancy, Disease Activity and Adverse Pregnancy Outcomesin Patients with Systemic Lupus Erythematosus
SLE – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Manifestations
9:00AM-11:00AM
Abstract Number: 0065
The Energy-dependent Hierarchy of Immune Functions in Human Monocytes
Innate Immunity Poster
9:00AM-11:00AM
Abstract Number: 0350
The Impact of Age and Time Since Diagnosis on Response to Treatment with Secukinumab in Pooled Week 52 Data from 4 Phase 3 Studies in Patients with Ankylosing Spondylitis
Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster I
9:00AM-11:00AM
Abstract Number: 0134
The Impact of Exercise on Sleep in People with Rheumatoid Arthritis: A Pilot Randomised Controlled Trial
Patient Outcomes, Preferences, & Attitudes Poster I: RA, Spondyloarthritis, & OA
9:00AM-11:00AM
Abstract Number: 0325
The Impact of PsA Disease Control Status on Patient Treatment Satisfaction: Real-world Survey in US and Europe
Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster I: Psoriatic Arthritis
  • «Previous Page
  • 1
  • …
  • 23
  • 24
  • 25
  • 26
  • 27
  • …
  • 35
  • Next Page»
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology